登录

Hongyu Medical Closes on ¥30M Series A Round, Providing Interventional Treatment of Heart Disease in Pet Dogs

Mailman 2020-03-31 19:12

泓宇医疗
http://www.hongyumedtech.com
企业数据由 动脉橙 提供支持
宠物犬心脏治疗器械研发商 | A轮 | 运营中
中国-浙江
2020-03-27
融资金额:RMB¥3000万
中信产业基金
查看

According to lieyunwang.com, Zhejiang Hongyu Medical Technology Co., Ltd. ("Hongyu Medical") has announced the completion of a ¥30 million Series A financing, led by CITICPE with participation from LYZZ Capital. Proceeds of this fund will be used for the global market business of Hongyu Medical’s intervention equipment for mitral valve disease in dogs.


As the first research and development company specializing in the interventional treatment of heart disease in pet dogs, Hongyu Medical is committed to the interventional treatments and fills the gap of cardiac treatment equipment in pet dogs. Currently, it is cooperating with many top veterinary hospitals in the world, and its products have entered the clinical stage in more than 30 developed countries, such as the United States, Britain, France, Germany and Japan, which are expected to achieve scale sales in the second half of 2020.


Established in July 2019, Hongyu Medical has built the first specialized heart surgery center in China -- Shanghai-based Xinyu Pet Hospital, focusing on heart disease diagnosis and treatment and minimally invasive interventional surgery for dogs. In addition, the center will provide cardiac interventional therapy training for global medical staff. It aims to become a global center of minimally invasive interventional therapy for the mitral valve in Asia and the world.


With high safety, small trauma, rapid recovery, and no need for cardiac arrest and cardiopulmonary bypass, the V-CLAMP surgery of Hongyu Medical offers a new solution for the treatment of mitral regurgitation in pet dogs by performing a 2-3cm incision in the anterior heart area and delivering the instrument to the heart through the puncture to complete mitral valve repair.


>>>>

About CITIC Private Equity Funds Management Co., Ltd. (CITICPE)


Founded in 2008, CITICPE is a leading asset management firm that manages multiple asset classes, including private equity, mezzanine and public market funds and other products, for a group of over 200 domestic and international investors. The company concentrates on buy-out scenarios and focus on five key sectors, including Technology & Internet, Industry & Energy, Finance & Business Services, Consumer & Leisure, and Healthcare.


>>>>

About LYZZ Capital


LYZZ Capital is a leading global healthcare-dedicated VC/PE firm. We currently are actively investing out of USD and RMB funds totaling over USD$360 million. Its team's biotech investment experience extends back over 15 years.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

中国糖尿病研究人员证明早期胰岛素治疗对心血管健康有显著益处

BioSpace 2024-06-19 18:39

罕见病患者呼吁新任联邦卫生部长提供持续资金和紧急政策干预

Medgate Today 2024-06-19 18:31

中国肿瘤整合诊治指南 —脑胶质瘤

MedSci 2024-06-19 18:31

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

中信产业基金

市场化独立运作的资产管理机构

立即沟通

泓宇医疗

宠物犬心脏治疗器械研发商

立即沟通

醴泽资本

风险投资管理机构

立即沟通
产业链接
查看更多